Average Insider

Where insiders trade, we follow

$CGON
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
Healthcare
Sector
Biotechnology
Industry
Arthur Kuan
CEO
113
Employees
$65.08
Current Price
$4.41B
Market Cap
52W Low$14.80
Current$65.0892.2% above low, 7.8% below high
52W High$69.35

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00--All Sells
Sells12$124,714.001,964
2 weeksBuys00--All Sells
Sells12$124,714.001,964
1 monthBuys00--All Sells
Sells12$124,714.001,964
2 monthsBuys00--All Sells
Sells12$124,714.001,964
3 monthsBuys00--All Sells
Sells14$709,512.7313,109
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Mar 16, 2026
Mulay James
Director
Sale654$63.50$41,529.00View Details
Mar 16, 2026
Mulay James
Director
Sale1,310$63.50$83,185.00View Details
Jan 9, 2026
Mulay James
Director
Sale654$44.16$28,880.64View Details
Jan 9, 2026
Mulay James
Director
Sale10,491$52.99$555,918.09View Details
21 more transactions available โ€” create a free account to see 12 months of history

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
No past earnings data available
Version: v26.3.23